RT Journal Article
SR Electronic
T1 Quantifying the role of naturally- and vaccine-derived neutralizing antibodies as a correlate of protection against COVID-19 variants
JF medRxiv
FD Cold Spring Harbor Laboratory Press
SP 2021.05.31.21258018
DO 10.1101/2021.05.31.21258018
A1 Jamie A. Cohen
A1 Robyn M. Stuart
A1 Katherine Rosenfeld
A1 Hil Lyons
A1 Michael White
A1 Cliff C. Kerr
A1 Daniel J. Klein
A1 Michael Famulare
YR 2021
UL http://medrxiv.org/content/early/2021/09/28/2021.05.31.21258018.abstract
AB The functional relationship between neutralizing antibodies (NAbs) and protection against SARS-CoV-2 infection and disease remains unclear. We jointly estimated protection against infection and disease progression following natural infection and vaccination from meta-study data. We find that NAbs are strongly correlated with prevention of infection and that any history of NAbs will stimulate immune memory to moderate disease progression. We also find that natural infection provides stronger protection than vaccination for the same level of NAbs, noting that infection itself, unlike vaccination, carries risk of morbidity and mortality, and that our most potent vaccines induce much higher NAb levels than natural infection. These results suggest that while sterilizing immunity may decay, we expect protection against severe disease to be robust over time and in the face of immune-evading variants.Competing Interest StatementThe authors have declared no competing interest.Funding StatementFunding was provided by the Bill and Melinda Gates Foundation.Author DeclarationsI confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.YesThe details of the IRB/oversight body that provided approval or exemption for the research described are given below:N/AAll necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived.YesI understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).YesI have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.YesAll data and code are freely available. https://github.com/amath-idm/COVID-Immune-Modeling